Corvus Pharmaceuticals (NASDAQ: CRVS) Sees Positive Developments
Corvus Pharmaceuticals(US:CRVS) Financial Modeling Prep·2026-01-21 03:00Barclays maintains an "Overweight" rating for CRVS, raising its price target from $16 to $28.CRVS announced a $150 million public offering to fund working capital and corporate purposes.Positive Phase 1 trial data for soquelitinib shows strong efficacy and safety, doubling CRVS stock price.Corvus Pharmaceuticals (NASDAQ: CRVS) is a clinical-stage biopharmaceutical company based in South San Francisco, focusing on developing innovative therapies for immune-related diseases. Recently, Barclays maintained an " ...